spacer
  Home | About CDC | Press Room | Funding | A-Z Index | Centers, Institute & Offices | Training & Employment | Contact Us
spacer
spacer CDC Centers for Disease Control and Prevention Home Page spacer
CDC en Español
spacer
 
spacer
Health & Safety TopicsPublications & ProductsData & StatisticsConferences & Events
spacer
spacer
spacer
spacer
  MLP Content
space
arrow Monitoring
space
arrow Coagulation
space
arrow QC Conference
space
arrow QI Conference
space
arrow Personnel
space
  Related Content
space
arrow DLS Home
space
arrow CLIA
space
arrow Genetics
space
arrow International
space
arrow IQLM
space
arrow MASTER
space
arrow MPEP
space
arrow NLTN
space
arrow Publications
space
arrow Training
space
spacer spacer
spacer
spacer
spacer
Quality Institute Conference 2003 - Abstract 16
spacer
spacer
  Image of the QI Conference Logo

DHHS Logo
  CDC Logo

   

Coagulation Laboratory Testing Practices in a 2001 Survey of 800 Randomly Selected U.S. Hospitals

S. Shahangian, A.K. Stankovic, I.M. Lubin, J.H. Handsfield, and M.D. White

Div Lab Systems, CDC, Atlanta, GA 30341-3717

Objective:

To assess variability of hospital coagulation laboratory practices.

Outcome:

Prevalence of selected laboratory practices.

Methods and Setting:

From a sampling frame of institutions listed in the 1999 directory of the American Hospital Association, we randomly selected 800 hospital coagulation laboratories (sampling rate, 14%). Six-hundred and thirty-two responded (response rate, 79%). A group of coagulation experts and survey methodologists assisted in the design of this 2001 survey, and they further evaluated the content and format of the survey before pilot testing. We excluded inconsistent responses from further analysis.

Results:

Ninety-seven percent stated they performed coagulation testing. Almost all (99.8%) reported PT results as international normalized ratio (INR), 97% reported results in seconds and/or as therapeutic PT ratio, and 3% reported results as INR only. Seventy-five percent reported using 3.2% sodium citrate as anticoagulant, and 27% reported using 3.8% sodium citrate. Seventeen percent reported determining the sensitivity of PT assay to heparin, and 50% reported selecting PT-thromboplastin reagents insensitive to heparin in the heparin therapeutic range. Sixty-four percent reported they had an aPTT therapeutic range for heparin when monitoring heparin therapy. Ninety-six percent assayed specimens for aPTT within 4 hours after phlebotomy, and 88% centrifuged specimens within 1 hour of collection. Fourteen percent reported monitoring low molecular weight heparin (LMWH) therapy; 72% used aPTT assay to monitor LMWH therapy while 53% used an anti-Xa assay to do so.

Generalizability:

Due to the high response and sampling rates, results of this survey appear to be generalizable.

Conclusion:

We found substantial variability in certain coagulation laboratory practices. Some of these practices are not consistent with current guidelines, and they may affect patient outcome. This calls for concerted intervention efforts.

     

This page last reviewed: 7/12/2004
spacer
spacer
spacer
spacer
  Home | Policies and Regulations | Disclaimer | e-Government | FOIA | Contact Us
spacer
spacer
spacer Safer, Healthier People
spacer
Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333, U.S.A
Tel: (404) 639-3311 / Public Inquiries: (404) 639-3534 / (800) 311-3435
spacer FirstGovDHHS Department of Health
and Human Services